CAJ | 학술논문

目的：探讨XRCC1基因Arg194Trp、Arg399Gln单核苷酸多态性(SNP)与外生型宫颈鳞状细胞癌放疗敏感性的关系。方法选择经组织病理学确诊的外生型宫颈鳞状细胞癌患者73例。其中临床分期Ⅰ期4例，Ⅱ期36例，Ⅲ期30例，Ⅳ期3例。肿瘤直径≤4 cm 30例，肿瘤直径＞4 cm 43例；A点剂量≤80 Gy者36例，A点剂量＞80 Gy者37例。近期疗效为完全缓解者(CR组)47例，部分缓解者(PR组)26例。采用错配扩增聚合酶链式反应检测患者血液标本的XRCC1 Arg194Trp、Arg399Gln SNP的基因型频率分布，分析其与宫颈癌放疗敏感性的关系。结果 XRCC1基因Arg194Trp分型中，携带Arg/Arg、Arg/Trp、TrP/Trp分别有31例（42.5%）、37例（50.7%）、5例（6.8%）；Arg399Gln分型中，携带Arg/Arg、Arg/Gln、Gln/Gln分别有26例（35.6%）、39例（53.4%）、8例（11.0%）。CR组与PR组Arg194Trp、Arg399Gln基因型分布差异均无统计学意义。影响放疗敏感性的多因素Logistic回归分析结果显示，临床分期晚为PR的危险因素。结论 XRCC1基因Arg194TrpSNP、Arg399Gln SNP与外生型宫颈鳞状细胞癌放疗敏感性无相关性。临床分期越晚放疗敏感性越差。
목적：탐토XRCC1기인Arg194Trp、Arg399Gln단핵감산다태성(SNP)여외생형궁경린상세포암방료민감성적관계。방법선택경조직병이학학진적외생형궁경린상세포암환자73례。기중림상분기Ⅰ기4례，Ⅱ기36례，Ⅲ기30례，Ⅳ기3례。종류직경≤4 cm 30례，종류직경＞4 cm 43례；A점제량≤80 Gy자36례，A점제량＞80 Gy자37례。근기료효위완전완해자(CR조)47례，부분완해자(PR조)26례。채용착배확증취합매련식반응검측환자혈액표본적XRCC1 Arg194Trp、Arg399Gln SNP적기인형빈솔분포，분석기여궁경암방료민감성적관계。결과 XRCC1기인Arg194Trp분형중，휴대Arg/Arg、Arg/Trp、TrP/Trp분별유31례（42.5%）、37례（50.7%）、5례（6.8%）；Arg399Gln분형중，휴대Arg/Arg、Arg/Gln、Gln/Gln분별유26례（35.6%）、39례（53.4%）、8례（11.0%）。CR조여PR조Arg194Trp、Arg399Gln기인형분포차이균무통계학의의。영향방료민감성적다인소Logistic회귀분석결과현시，림상분기만위PR적위험인소。결론 XRCC1기인Arg194TrpSNP、Arg399Gln SNP여외생형궁경린상세포암방료민감성무상관성。림상분기월만방료민감성월차。
Objective To investigate the correlation of XRCC1 Arg194Trp Arg399Gln Single nucleotide polymor-phism (SNP) with radiotherapy response of squamous cell carcinoma of cervix. Methods Patients with exogenous type cer-vical squamous cell carcinoma confirmed by histopathology were selected for our study. These include:patients in stageⅠ(4 cases), patients in stageⅡ(36 cases), patients in stageⅢ(30 cases), patients in stageⅣ (3 cases). There are 30 patients with tumor diameter less than 4 cm and 43 patients with tumor diameter over 4 cm in our test. There are 36 cases with dose point A less than 80 Gy and 37 cases with dose point A over 80 Gy . Radiotherapy outcomes showed 47 cases of complete re-mission and 26 cases of part remission. Polymorphisms Arg194Trp, Arg399Gln of XRCC1 gene in 73 cervical cancer pa-tients were analyzed by mismatch amplification polymerase chain reaction (MAMA-PCR). Results Arg/Arg, Arg/Trp, TrP/Trp of Arg194Trp genotype distribution were 31 (42.5%), 37 (50.7%), 5 (6.8%) respectively. Arg/Arg, Arg/Gln, Gln/Gln of Arg399Gln distribution were 6 (35.6%), 39 (53.4%), 8 (11.0%) respectively. The response to radiotherapy was not statistical-ly significant in three genotypes, Arg/Arg, Arg/Trp, TrP/Trp of XRCC1 at codon 194(P>0.05). Neither was XRCC1 at codon 399. Multivariate analysis showed that late clinical stage was a risk factor of part remission. Conclusion SNP of XRCC1 gene at codon 194 and codon 399 could not predict clinical response of patients with squamous cell carcinoma of cervix to ra-diotherapy. The patients with advanced cervical cancer had poor response to radiotherapy.